Single-dose pharmacokinetics of cefpirome in patients receiving hemodialysis and in patients treated by continuous ambulatory peritoneal dialysis

• Published in: Clinical pharmacology and therapeutics Vol. 54; no. 4; p. 395
• Main Authors: Veys, N, Lameire, N, Malerczyk, V, Lehr, K H, Rosenkranz, B, Ringoir, S
• Format: Journal Article
• Language: English
• Published: United States 01.10.1993
• Subjects: Adult; Aged; Biological Availability; Cefpirome; Cephalosporins - administration & dosage; Cephalosporins - pharmacokinetics; Female; Humans; Kidney Failure, Chronic - metabolism; Kidney Failure, Chronic - therapy; Male; Middle Aged; Models, Biological; Peritoneal Dialysis, Continuous Ambulatory; Renal Dialysis
• ISSN: 0009-9236
• DOI: 10.1038/clpt.1993.166

Cefpirome is eliminated primarily by renal excretion, compelling dosage reduction in kidney failure. We studied the elimination kinetics after intravenous administration of 1 gm cefpirome in patients undergoing hemodialysis (n = 9) and after intravenous (n = 6) or intraperitoneal administration (n = 6) of 1 gm cefpirome in subjects treated by continuous ambulatory peritoneal dialysis (CAPD). Four hours of hemodialysis removed 48% +/- 9% of the drug present in the body at the start of hemodialysis. Consequently, a supplementary dose equal to 50% of the daily dose recommended in end stage renal disease (ESRD) should be administered after each hemodialysis treatment. In patients receiving CAPD, therapeutic levels in both serum and dialysate were reached after intravenous and intraperitoneal administration. The bioavailability after intraperitoneal administration was 84%. After systemic administration, the elimination of cefpirome in the dialysate was negligible. Consequently, systemic dosage of cefpirome in patients receiving CAPD and in patients with ESRD should be identical.